image
DBV Technologies S.A. DBVT
Healthcare - Biotechnology - NASDAQ - FR
Watchlist
$ 9.7
2.99 %
$ 265 M
Market Cap
-1.74
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one DBVT stock under the worst case scenario is HIDDEN Compared to the current market price of 9.7 USD, DBV Technologies S.A. is HIDDEN

DBVT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one DBVT stock under the base case scenario is HIDDEN Compared to the current market price of 9.7 USD, DBV Technologies S.A. is HIDDEN

DBVT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one DBVT stock under the best case scenario is HIDDEN Compared to the current market price of 9.7 USD, DBV Technologies S.A. is HIDDEN

DBVT Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart DBVT

image
1M 9%
6M 120%
1Y 66%
3Y -163%
5Y -315%
All
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
2.57 M REVENUE
-83.67%
Growth Rates
1Year -83.67%
3Years -23.38%
5Years -29.46%
7Years -19.30%
10Years 25.90%
-117 M OPERATING INCOME
-52.54%
Growth Rates
1Year -52.54%
3Years -5.74%
5Years 7.38%
7Years 5.55%
10Years -14.61%
-114 M NET INCOME
-56.64%
Growth Rates
1Year -56.64%
3Years -5.21%
5Years 10.21%
7Years 8.23%
10Years -11.63%
-104 M OPERATING CASH FLOW
-31.16%
Growth Rates
1Year -31.16%
3Years 1.17%
5Years 8.55%
7Years 5.98%
10Years -12.40%
-757 K INVESTING CASH FLOW
6.31%
Growth Rates
1Year 6.31%
3Years -20.47%
5Years 34.81%
7Years 31.80%
10Years 7.93%
587 K FINANCING CASH FLOW
-91.33%
Growth Rates
1Year -91.33%
3Years 28.91%
5Years -69.76%
7Years 5.54%
10Years -42.66%
0 REVENUE
0.00%
Growth Rates
1Year -83.67%
3Years -23.38%
5Years -29.46%
7Years -19.30%
10Years 25.90%
-27.4 M OPERATING INCOME
-14.71%
Growth Rates
1Year -52.54%
3Years -5.74%
5Years 7.38%
7Years 5.55%
10Years -14.61%
-27.1 M NET INCOME
100.00%
Growth Rates
1Year -56.64%
3Years -5.21%
5Years 10.21%
7Years 8.23%
10Years -11.63%
-19.7 M OPERATING CASH FLOW
-60.53%
Growth Rates
1Year -31.16%
3Years 1.17%
5Years 8.55%
7Years 5.98%
10Years -12.40%
-375 K INVESTING CASH FLOW
-47.29%
Growth Rates
1Year 6.31%
3Years -20.47%
5Years 34.81%
7Years 31.80%
10Years 7.93%
45 K FINANCING CASH FLOW
-93.33%
Growth Rates
1Year -91.33%
3Years 28.91%
5Years -69.76%
7Years 5.54%
10Years -42.66%
Balance Sheet DBV Technologies S.A.
image
Current Assets 44.4 M
Cash & Short-Term Investments 32.5 M
Receivables 10.4 M
Other Current Assets 1.54 M
Non-Current Assets 21.3 M
Long-Term Investments 4.31 M
PP&E 16.8 M
Other Non-Current Assets 151 K
49.43 %15.83 %6.57 %25.60 %Total Assets$65.7m
Current Liabilities 31.1 M
Accounts Payable 22 M
Short-Term Debt 1.5 M
Other Current Liabilities 7.6 M
Non-Current Liabilities 7.14 M
Long-Term Debt 6.3 M
Other Non-Current Liabilities 838 K
57.57 %3.92 %19.87 %16.45 %Total Liabilities$38.3m
EFFICIENCY
Earnings Waterfall DBV Technologies S.A.
image
Revenue 2.57 M
Cost Of Revenue 6.83 M
Gross Profit -4.26 M
Operating Expenses 114 M
Operating Income -117 M
Other Expenses -2.67 M
Net Income -114 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)3m(7m)(4m)(114m)(117m)3m(114m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years -74.30%
5Years -57.07%
7Years -40.77%
10Years -24.87%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years -833.04%
5Years -845.35%
7Years -603.82%
10Years -2677.43%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years -822.88%
5Years -836.44%
7Years -597.46%
10Years -2629.80%
0.00% ROE
0.00%
Averages
1Year 0.00%
3Years -33.80%
5Years -55.51%
7Years -72.00%
10Years -67.87%
0.00% ROA
0.00%
Averages
1Year 0.00%
3Years -26.27%
5Years -40.82%
7Years -52.05%
10Years -50.03%
0.00% ROIC
0.00%
Averages
1Year 0.00%
3Years -32.18%
5Years -50.01%
7Years -64.90%
10Years -61.41%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis DBV Technologies S.A.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -114 M
Depreciation & Amortization -925 K
Capital Expenditures -2.34 M
Stock-Based Compensation 4.62 M
Change in Working Capital 5.75 M
Others 5.48 M
Free Cash Flow -107 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets DBV Technologies S.A.
image
Wall Street analysts predict an average 1-year price target for DBVT of $16 , with forecasts ranging from a low of $16 to a high of $16 .
DBVT Lowest Price Target Wall Street Target
16 USD 64.95%
DBVT Average Price Target Wall Street Target
16 USD 64.95%
DBVT Highest Price Target Wall Street Target
16 USD 64.95%
Price
Max Price Target
Min Price Target
Average Price Target
161614141212101088664422Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership DBV Technologies S.A.
image
Sold
0-3 MONTHS
730 USD 1
3-6 MONTHS
510 USD 1
6-9 MONTHS
1.77 K USD 1
9-12 MONTHS
1.75 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe. globenewswire.com - 1 month ago
DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. globenewswire.com - 1 month ago
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. globenewswire.com - 1 month ago
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. globenewswire.com - 1 month ago
Are Medical Stocks Lagging DBV Technologies (DBVT) This Year? Here is how DBV Technologies S.A. (DBVT) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year. zacks.com - 2 months ago
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. Does DBV Technologies S.A. (DBVT) have what it takes to be a top stock pick for momentum investors? zacks.com - 2 months ago
DBV Technologies (DBVT) Is a Great Choice for 'Trend' Investors, Here's Why DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com - 2 months ago
Combined General Meeting of June 11, 2025 Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. globenewswire.com - 2 months ago
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event. globenewswire.com - 2 months ago
DBV Technologies Reports First Quarter 2025 Financial Results Châtillon, France, April 30, 2025   DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. globenewswire.com - 2 months ago
Here's Why Momentum in DBV Technologies (DBVT) Should Keep going DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com - 2 months ago
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes from the unaudited financial statements examined by the Board of Directors on March 23 and published in the Company's press release dated March 24, 2025; The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the 2024 URD includes the following information: The Annual Financial Report; The Management Report (“rapport de gestion”); The Corporate Governance Report; The description of the Share Buyback Program. globenewswire.com - 3 months ago
8. Profile Summary

DBV Technologies S.A. DBVT

image
COUNTRY FR
INDUSTRY Biotechnology
MARKET CAP $ 265 M
Dividend Yield 0.00%
Description DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Contact 177-181 Avenue Pierre Brossolette, Montrouge, 92120 https://www.dbv-technologies.com
IPO Date Oct. 22, 2014
Employees 106
Officers Ms. Michele F. Robertson Chief Legal Officer Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. Chief Financial Officer Dr. Pharis Mohideen M.D. Chief Medical Officer Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. Chief Operations Officer Dr. Robert G. Pietrusko Pharm. D., Pharm.D. Chief Regulatory Officer Ms. Caroline Daniere Chief Human Resources Officer & Chief of Staff Mr. Pascal Wotling Chief External Manufacturing & Supply Chain Officer Katie Matthews Investor Relations Officer Mr. Daniel Tassé Chief Executive Officer & Director Alan Kerr Senior Vice President & Head of Global Regulatory Affairs